NervGEN Pharma ($NGENF)–Unleashing the Nervous System to REPAIR and Heal Itself

NervGEN Pharma ( NGENF ) is a public company.  www.nervgen.com

NervGEN is unleashing the Nervous System to Repair and  Heal Itself-Focusing on multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).  NervGEN’s technology is applicable to all Nervous System Diseases.

Based upon thirty years of research by Dr. Jerry Silvers Case University and Cleveland Clinic

PHD left AMGEN to become Chief Medical Officer of NervGEN Dr Dan Mikol. Reason: Dr Silvers 30 years of research

Founding and current Editor of Journal of Alzheimer’s Disease Dr George Perry is on the NervGEN Advisory Board

Dr George Perry has stated: “If you have a drug that actually changes the biology of the disease (i.e. NervGEN’s NVG -291) why do you need 100’s to see (in clinical trial)?  …….NervGEN’s NVG-291 “may change the course of the disease…maybe not full recovery….. “I am actually quite enthusiastic.”

NervGEN likely to receive nondilutive financing from the Department of Defense for Traumatic Brain Injury (TBI) Research

Dr Michael Davis- (Retired Colonel) –Traumatic Brain Injury and the Department of Defense “The mechanism of this (NervGEN peptide NVG-291) is unique….it’s had significant preclinical validation in the central nervous system…. I feel very strongly that this has high likely chance of success”

‘Proven functional recovery demonstrated in 6 different disease models with benefits crossing multiple neurological functions’

NervGEN is developing a revolutionary new class of drugs that REPAIRS damage to the Nervous System and restores motor sensory and cognitive function. Currently there are no approved “neurorestorative” drugs.

Delivered systemically via injection, NervGen’s drug (NVG-291) REPAIRS the nervous system at the site of damage with a mechanism of action that results in multiple modes of repair-including regeneration, remyelination and enhanced plasticity.

NervGEN’s published results from animal models of damage and disease are unprecedented both in scope and magnitude of effect, including spinal cord injury, multiple sclerosis (MS), stroke, cardiac arrythmia and peripheral nerve injury.

Backed by three decades of scientific research by Dr. Jerry Silvers, NervGEN’s platform technology has the potential to redefine therapeutic outcomes for ALL central nervous system damage-including multiple sclerosis (MS), Alzheimer’s disease, spinal cord injury, stroke and traumatic brain injury (TBI).

 NervGEN’s lead product, NVG-291, is the only drug of its kind in clinical development. Most nervous system drugs in development are aimed at stopping or SLOWING the progressive of the disease not REPAIRING. No treatment exists that “rewires” the damaged nerve connections and results in improvement.

NervGEN is hoping for Breakthrough Status from FDA on 3 fronts: Alzheimer’s Disease, MS and Spinal Cord Injury

In 2003 Dr Jerry Silvers was honored with the Christopher Reeve-Joan Irvine Research Medal (The Reeve-Irvine Medal) for critical contributions that may lead to the promotion of repair of the damaged spinal cord.

NervGen Pharma Zoom Presentation

See Mice Given NervGEN Drug NVG-291 – A MIRACLE

 9:24  Spinal Cord Injury

41:02 Spinal Cord Injury

55.18  MS Multiple Sclerosis 

Paradigm Capital NervGEN Analyst Report 10/13/21

Encode initiation report on NervGEN September 13, 2021

Revolutionary drug ‘could reverse damage’ caused by Alzheimer’s by allowing nerve cells to mend themselves, scientists say 

https://www.tech-gate.org/usa/2021/10/03/revolutionary-drug-could-reverse-damage-caused-by-alzheimers/

Dr Jerry Silvers

 NervGen’s Alzheimer’s Disease Clinical Advisory Board

Jeffrey Cummings, MD, ScD

Martin Farlow, MD

Bruce Lamb, PhD

George Perry, PhD  ( Founding and Current Editor-in-Chief Journal of Alzheimer’s Disease)

Reisa Sperling, MD

Michael Weiner, MD (Published over 903 peer-reviewed articles)

Henrik Zetterberg, MD, PhD

NervGEN’s Multiple Sclerosis Clinical Advisory Board

Jack Antel, MD

Peter Calabresi, MD

Jeremy Chataway, MD

Jeffrey Cohen, MD

Robert Naismith, MD

Anneke van der Walt, MD, PhD

Spinal Cord Injury Clinical Advisory Board

James Guest, MD, PhD, FACS

Steven Kirshblum, MD

Brian Kwon, MD, PhD, FRCSC

Linda Jones, PT, PhD

Linda Jones, PT, PhD

More Videos

**September 9, 2021 NervGen Annual Shareholders Meeting

CEO Paul Brennan 14:06 minutes Multiple preclinical predictors of human clinical success

Chief Medical Officer Dan Mikol Why he left Amgen to come to NervGen 18:30 to 33:10

CEO Paul Brennan Target indications are attractive markets with significant unmet needs 49:00

and upcoming Value Drivers 55:50

Dr. Michael R Davis 34:50 to 46:50  At 45:26 “I feel very strongly that this has high likely chance of success”

**June 18, 2021- NervGen’s Case for an Effective Alzheimer’s Treatment

New NervGEN Chief Medical Officer from AMGEN Dan Mikol MD PHD why he came to NervGEN

https://biopub-webcasts.s3.amazonaws.com/June+18%2C+2021+NervGen’s+Case+for+an+Effective+Alzheimer’s+Treatment

Dan Mikol–from  Amgen

24:38 minutes to  37:40 minutes

Dr. George Perry NervGen (NGENF) Advisory Board and founding and current editor of the Journal of Alzheimer’s Disease:

“If you have a drug that actually changes the biology of the disease (i.e. NervGen’s NVG -291) why do you need 100’s to see (in clinical trial)?  …….NervGen’s NVG-291 “may change the course of the disease…maybe not full recovery….. “I am actually quite enthusiastic.”

46:44  to 48:35 minutes

Rich McAry

59:11 minutes

Paul Brennan

1:43 one hour 43 minutes


**April 14 2021 NervGen WebCast includes introduction of Dr Michael Davis- (Retired Colonel) –Traumatic Brain Injury and the Department of Defense

“The mechamism of this (NervGEN peptide NVG-291) is unique….it’s had significant preclinical validation in the central nervous system…we really need to pursue preclinical work further.”

Dr. Michael R Davis 36:48 to 1:18:10

https://biopub-webcasts.s3.amazonaws.com/NervGen+April+14

**October 20, 2021- NervGen: A Key Update on New Phase 1 Data

NervGEN is hoping for Breakthrough Status from FDA on 3 fronts: Alzheimer’s Disease, MS and Spinal Cord Injury


‘Proven functional recovery demonstrated in 6 different disease models with benefits crossing multiple neurological functions’

Also there could be targets outside the Central Nervous System.  Dr Jerry Silvers is  on call.  30+ years of  research

Chief Medical Officer Dan Mikol

“I actually feel the results of spinal cord injury are especially exciting because spinal cord injury is not a disease it is consequence of trauma and if you can show repair in this condition where there is damage to the nervous system why shouldn’t this approach work in the other central nervous diseases like MS and Alzheimer’s….”

https://biopub-webcasts.s3.amazonaws.com/October+20%2C+2021-+NervGen%3A+A+Key+Update+on+New+Phase+1+Data

**27 JAN 2021 – BioPub.co Presents: NervGen – Alzheimer’s in its Bombsights

**16 DEC 2020 – NervGen WebCast: Maximizing Value, NervGen’s Indication Strategy and Operational Update

**26 JUN 2020 – BioPub.co Presents: Dr. Jerry Silver -BioPub’s “Evergreen” Scientist of the Year

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s